Covid19 Treatment Studies
Treatment Studies
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Noteworthy: “Health personnel are one of the most exposed groups to COVID-19 because of their steady contact with infected patients. In this study, treatment with IVER/IOTACRC for pre-exposure prophylaxis to COVID-19 has shown a protective effect over the control group. People infected with COVID-19 at the end of the follow-up was significantly higher in the CG compared with the EG”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415509/
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 (Monoclonals) Noteworthy: “By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab–etesevimab group had a Covid-19–related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, −4.8 percentage points; 95% confidence interval [CI], −7.4 to −2.3; relative risk difference, 70%; P<0.001). No deaths occurred in the bamlanivimab–etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19–related.”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314785/